Purchase this article with an account.
Marie-Claude Robert, Mathieu Frenette, Chengxin Zhou, Yueran Yan, James Chodosh, Frederick A. Jakobiec, Anna M. Stagner, Demetrios Vavvas, Claes H. Dohlman, Eleftherios I. Paschalis; A Drug Delivery System for Administration of Anti–TNF-α Antibody. Trans. Vis. Sci. Tech. 2016;5(2):11. doi: 10.1167/tvst.5.2.11.
Download citation file:
© 2017 Association for Research in Vision and Ophthalmology.
To describe the fabrication, evaluation, and preliminary in vivo safety of a new drug delivery system (DDS) for topical anti–TNF-α antibody administration.
A DDS was fabricated using inverse template fabrication of a hydrophobic three-dimensional porous scaffold (100–300 μm in diameter porosity) loaded with 10% polyvinyl alcohol hydrogel carrying 5 mg/ml (weight/volume) of anti–TNF-α antibody. Drug-loaded DDS was sterilized with 25 kGy of gamma irradiation. Long-term in vitro antibody affinity and release was evaluated at room temperature or 37°C using enzyme-linked immunosorbent assay (ELISA) and protein fluorescence. In vivo clinical and histolopathological assessment was performed by subcutaneous implantation in BALB/c mice for 3 months.
Gamma irradiation, repeated dry/wet cycles, and storage at room temperature for 1 year or 37°C for 1 month had no deleterious effects on antibody affinity. Anti–TNF-α release was high during the first minutes of aqueous exposure, followed by stabilization and gradual, low-dose, antibody release over the next 30 days. Histopathologic evaluation of explanted DDS showed a fibrous pseudocapsule and a myxoid acute/chronic inflammation without granuloma formation surrounding the implants.
Sustained local delivery of anti–TNF-α antibody is feasible using the described DDS, which provides stability of the enclosed antibody for up to 1 year of storage. Preliminary results show good in vivo tolerance following subcutaneous placement for 3 months. The proposed fabrication and sterilization process opens new possibilities for the delivery of biologic agents to the anterior surface of the eye.
The described DDS will facilitate the treatment of ocular surface diseases amenable to biologic therapy.
This PDF is available to Subscribers Only